Wild type NRAS
About
Gene context: NRAS
Biomarker Type: Wild type
Present: True
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab | |
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Irinotecan | |
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Oxaliplatin | |
| EMA (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Oxaliplatin, Panitumumab | |
| EMA (2) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Irinotecan, Panitumumab | |
| EMA (1) HSE (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Panitumumab | |
| HSE (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Irinotecan | |
| FDA (1) | HER2-positive, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Trastuzumab, Tucatinib |